spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Rapaflo 

 HSMN NewsFeed - 14 Jan 2014
Actavis Appoints Industry Veterans to Lead U.S. Specialty Brands Business Units
Biopharmaceuticals Urology Gastroenterology Personnel
 HSMN NewsFeed - 19 Jun 2013
Actavis And Kissei File Lawsuits Against Sandoz And Hetero For Infringement Of Rapaflo(R) Patent
Biopharmaceuticals Urology Generics Litigation
 HSMN NewsFeed - 16 Dec 2010
Watson and Richter Announce Exclusive License Agreement for Esmya
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Aug 2010
Watson Plans Q4 2010 ella(R) (ulipristal acetate) Emergency Contraceptive Launch
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Mar 2010
Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' CRINONE(R) Progesterone Gel Product Line
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 1 Feb 2010
Watson and HRA Pharma Announce Exclusive Licensing Agreement to Commercialize Novel Emergency Contraceptive in the U.S.
Biopharmaceuticals Licensing
 HSMN NewsFeed - 9 Dec 2009
New Published Data Demonstrate Long-Term Safety, Efficacy and Tolerability of Watson's RAPAFLO(R) (silodosin) for Benign Prostatic Hyperplasia (BPH) Symptom Relief
Biopharmaceuticals Urology
 HSMN NewsFeed - 21 May 2009
Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
Biopharmaceuticals Urology
 HSMN NewsFeed - 8 May 2009
RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
Biopharmaceuticals Urology
 HSMN NewsFeed - 7 Apr 2009
Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
Biopharmaceuticals Urology
 HSMN NewsFeed - 27 Jan 2009
Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
Biopharmaceuticals Drug Delivery Urology FDA
 HSMN NewsFeed - 8 Oct 2008
Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
Biopharmaceuticals FDA Urology
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.